Literature DB >> 11101487

Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome.

M Olesen1, E Gudmand-Hoyer.   

Abstract

BACKGROUND: Interest in fructooligosaccharides as a health-promoting food component is increasing. Fructooligosaccharides are mainly indigestible and large amounts in the colon may provoke gastrointestinal symptoms.
OBJECTIVE: The symptoms of irritable bowel syndrome (IBS) may be provoked by large quantities of carbohydrates in the colon. The objective of this study was to determine whether regular consumption of fructooligosaccharides worsens gastrointestinal symptoms in patients with IBS.
DESIGN: A multicenter, prospective, randomized, double-blind, placebo-controlled parallel group comparison was conducted at 24 sites. The study consisted of a 2-wk, single-blind run-in phase and a 12-wk, double-blind comparative phase. Subjects were randomly assigned to receive 20 g fructooligosaccharides powder/d (n = 52) or a placebo (n = 46). Efficacy was based on the patients' overall response to treatment at completion of the study and on the severity and duration of individual symptoms (abdominal distension, abdominal rumbling, abnormal flatulence, and abdominal pain).
RESULTS: Data from 96 patients (16 men and 80 women) were analyzed. After 4-6 wk of treatment, IBS symptoms improved more in the placebo group than in the fructooligosaccharide group. After completion of the study, there were no significant differences between the 2 groups: symptoms improved in 58% of the fructooligosaccharide group and in 65% of the placebo group and symptoms worsened in 8% of the fructooligosaccharide group and in 13% of the placebo group.
CONCLUSION: Although symptoms worsened in patients with IBS at the onset of treatment with 20 g fructooligosaccharides/d, continuous treatment for 12 wk resulted in no worsening of symptoms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11101487     DOI: 10.1093/ajcn/72.6.1570

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  26 in total

1.  Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals?

Authors:  Jacqueline S Barrett; Peter R Gibson
Journal:  Therap Adv Gastroenterol       Date:  2012-07       Impact factor: 4.409

Review 2.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

3.  The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial.

Authors:  Octavian Alexea; Vlad Bacarea; Núria Piqué
Journal:  United European Gastroenterol J       Date:  2015-10-30       Impact factor: 4.623

Review 4.  Brain-gut microbiome interactions and functional bowel disorders.

Authors:  Emeran A Mayer; Tor Savidge; Robert J Shulman
Journal:  Gastroenterology       Date:  2014-02-28       Impact factor: 22.682

Review 5.  Dietary fibre in gastrointestinal health and disease.

Authors:  Samantha K Gill; Megan Rossi; Balazs Bajka; Kevin Whelan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-11-18       Impact factor: 46.802

6.  Starch-entrapped microsphere fibers improve bowel habit but do not exhibit prebiotic capacity in those with unsatisfactory bowel habits: a phase I, randomized, double-blind, controlled human trial.

Authors:  Heather E Rasmussen; Bruce Hamaker; Kumar B Rajan; Ece Mutlu; Stefan J Green; Michael Brown; Amandeep Kaur; Ali Keshavarzian
Journal:  Nutr Res       Date:  2017-06-02       Impact factor: 3.315

Review 7.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

Review 8.  Chili Peppers, Curcumins, and Prebiotics in Gastrointestinal Health and Disease.

Authors:  Tanisa Patcharatrakul; Sutep Gonlachanvit
Journal:  Curr Gastroenterol Rep       Date:  2016-04

Review 9.  The intestinal microbiome, probiotics and prebiotics in neurogastroenterology.

Authors:  Delphine M Saulnier; Yehuda Ringel; Melvin B Heyman; Jane A Foster; Premysl Bercik; Robert J Shulman; James Versalovic; Elena F Verdu; Ted G Dinan; Gail Hecht; Francisco Guarner
Journal:  Gut Microbes       Date:  2012-11-30

10.  Targeting the Microbiota, from Irritable Bowel Syndrome to Mood Disorders: Focus on Probiotics and Prebiotics.

Authors:  M M Pusceddu; K Murray; M G Gareau
Journal:  Curr Pathobiol Rep       Date:  2018-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.